Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oncomed Pharmaceuticals Inc (OMED) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Oncomed Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1302573.
Total stock buying since 2014: $2,268,757.
Total stock sales since 2014: $14,488,576.
Total stock option exercises since 2014: $599,033.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2018 | 0 | $0 | 46,794 | $93,960 | 0 | $0 |
| 2017 | 88,121 | $304,301 | 139,790 | $1,024,633 | 71,328 | $115,234 |
| 2016 | 0 | $0 | 29,845 | $499,205 | 15,000 | $29,274 |
| 2015 | 24,350 | $366,668 | 172,787 | $4,104,165 | 122,900 | $345,699 |
| 2014 | 84,418 | $1,597,788 | 391,276 | $8,766,613 | 69,539 | $108,826 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2018-12 | 0 | $0 | 11,117 | $6,670 | 0 | $0 |
| 2018-10 | 0 | $0 | 13,905 | $28,987 | 0 | $0 |
| 2018-04 | 0 | $0 | 21,772 | $58,303 | 0 | $0 |
| 2017-10 | 0 | $0 | 6,390 | $27,174 | 0 | $0 |
| 2017-06 | 10,000 | $34,590 | 0 | $0 | 0 | $0 |
| 2017-05 | 78,121 | $269,711 | 28,267 | $103,867 | 0 | $0 |
| 2017-04 | 0 | $0 | 33,805 | $303,023 | 0 | $0 |
| 2017-03 | 0 | $0 | 6,652 | $66,520 | 6,652 | $22,749 |
| 2017-01 | 0 | $0 | 64,676 | $524,049 | 64,676 | $92,485 |
| 2016-11 | 0 | $0 | 12,500 | $123,612 | 12,500 | $17,875 |
| 2016-01 | 0 | $0 | 17,345 | $375,593 | 2,500 | $11,399 |
| 2015-12 | 0 | $0 | 2,500 | $51,232 | 2,500 | $11,399 |
| 2015-11 | 0 | $0 | 4,300 | $94,575 | 4,300 | $17,555 |
| 2015-10 | 0 | $0 | 24,400 | $493,400 | 10,400 | $41,267 |
| 2015-09 | 24,350 | $366,668 | 0 | $0 | 0 | $0 |
| 2015-08 | 0 | $0 | 2,500 | $55,622 | 2,500 | $11,399 |
| 2015-07 | 0 | $0 | 20,800 | $434,622 | 6,800 | $28,954 |
| 2015-06 | 0 | $0 | 23,800 | $597,262 | 23,800 | $46,073 |
| 2015-05 | 0 | $0 | 5,800 | $132,567 | 1,800 | $6,156 |
| 2015-04 | 0 | $0 | 31,187 | $797,515 | 25,300 | $44,455 |
| 2015-03 | 0 | $0 | 23,500 | $649,943 | 19,500 | $68,398 |
| 2015-02 | 0 | $0 | 17,000 | $403,035 | 13,000 | $23,284 |
| 2015-01 | 0 | $0 | 17,000 | $394,392 | 13,000 | $46,759 |
| 2014-12 | 0 | $0 | 121,052 | $2,614,327 | 4,000 | $5,720 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-12-24 | Gurney Austin (See Remarks) | Sale | 11,117 | .60 | 6,670 |
| 2018-10-10 | Stagg Robert (SVP, Clinical R&D) | Sale | 927 | 2.01 | 1,863 |
| 2018-10-10 | Li Yvonne (See Remarks) | Sale | 927 | 2.02 | 1,872 |
| 2018-10-10 | Hager Alicia J. (SVP & General Counsel) | Sale | 1,156 | 2.02 | 2,335 |
| 2018-10-10 | Gurney Austin (See Remarks) | Sale | 1,156 | 2.01 | 2,323 |
| 2018-10-10 | Lewicki John A. (President & CEO) | Sale | 1,156 | 2.01 | 2,323 |
| 2018-10-09 | Stagg Robert (SVP, Clinical R&D) | Sale | 1,686 | 2.13 | 3,589 |
| 2018-10-09 | Li Yvonne (See Remarks) | Sale | 1,229 | 2.13 | 2,616 |
| 2018-10-09 | Hager Alicia J. (SVP & General Counsel) | Sale | 1,686 | 2.13 | 3,589 |
| 2018-10-09 | Gurney Austin (See Remarks) | Sale | 1,686 | 2.13 | 3,589 |
| 2018-10-09 | Lewicki John A. (President & CEO) | Sale | 2,296 | 2.13 | 4,888 |
| 2018-04-24 | Stagg Robert (SVP, Clinical R&D) | Sale | 4,051 | 2.68 | 10,848 |
| 2018-04-24 | Li Yvonne (See Remarks) | Sale | 5,062 | 2.68 | 13,556 |
| 2018-04-24 | Hager Alicia J. (SVP & General Counsel) | Sale | 4,051 | 2.68 | 10,848 |
| 2018-04-24 | Gurney Austin (See Remarks) | Sale | 4,051 | 2.68 | 10,848 |
| 2018-04-24 | Lewicki John A. (President & CEO) | Sale | 4,557 | 2.68 | 12,203 |
| 2017-10-10 | Hager Alicia J. (SVP & General Counsel) | Sale | 1,248 | 4.25 | 5,305 |
| 2017-10-10 | Gurney Austin (See Remarks) | Sale | 1,248 | 4.26 | 5,311 |
| 2017-10-10 | Lewicki John A. (EVP, Research & Development) | Sale | 1,248 | 4.25 | 5,305 |
| 2017-10-10 | Patel Sunil (See Remarks) | Sale | 1,248 | 4.26 | 5,311 |
| 2017-10-10 | Hastings Paul J (Chairman & CEO) | Sale | 1,398 | 4.25 | 5,942 |
| 2017-06-05 | Karsen Perry A | Buy | 10,000 | 3.46 | 34,590 |
| 2017-05-26 | Root Jonathan D (Director) | Sale | 9,580 | 3.70 | 35,465 |
| 2017-05-25 | Lasersohn Jack W | Buy | 34,614 | 3.37 | 116,649 |
| 2017-05-24 | Root Jonathan D (Director) | Sale | 4,300 | 3.72 | 15,978 |
| 2017-05-23 | Lasersohn Jack W | Buy | 20,000 | 3.55 | 71,000 |
| 2017-05-19 | Root Jonathan D (Director) | Sale | 7,487 | 3.70 | 27,709 |
| 2017-05-16 | Root Jonathan D (Director) | Sale | 6,900 | 3.58 | 24,715 |
| 2017-05-16 | Lasersohn Jack W | Buy | 23,507 | 3.49 | 82,062 |
| 2017-04-04 | Hager Alicia J. (SVP & General Counsel) | Sale | 4,316 | 8.97 | 38,697 |
| 2017-04-04 | Gurney Austin (See Remarks) | Sale | 5,754 | 8.96 | 51,573 |
| 2017-04-04 | Lewicki John A. (EVP, Research & Development) | Sale | 5,754 | 8.96 | 51,573 |
| 2017-04-04 | Hoey Timothy (SVP, Cancer Biology & Co-CSO) | Sale | 5,754 | 8.96 | 51,573 |
| 2017-04-04 | Patel Sunil (See Remarks) | Sale | 5,754 | 8.97 | 51,590 |
| 2017-04-04 | Hastings Paul J (Chairman & CEO) | Sale | 6,473 | 8.96 | 58,017 |
| 2017-03-15 | Hager Alicia J. (SVP & General Counsel) | Sale | 6,652 | 10.00 | 66,520 |
| 2017-03-15 | Hager Alicia J. (SVP & General Counsel) | Option Ex | 6,652 | 3.42 | 22,749 |
| 2017-01-06 | Hastings Paul J (Chairman & CEO) | Sale | 21,369 | 8.52 | 181,957 |
| 2017-01-06 | Hastings Paul J (Chairman & CEO) | Option Ex | 21,369 | 1.43 | 30,557 |
| 2017-01-05 | Hastings Paul J (Chairman & CEO) | Sale | 21,369 | 8.17 | 174,606 |
| 2017-01-05 | Hastings Paul J (Chairman & CEO) | Option Ex | 21,369 | 1.43 | 30,557 |
| 2017-01-03 | Lewicki John A. (EVP, Research & Development) | Sale | 9,175 | 7.63 | 70,041 |
| 2017-01-03 | Lewicki John A. (EVP, Research & Development) | Option Ex | 9,175 | 1.43 | 13,120 |
| 2017-01-03 | Hoey Timothy (SVP, Cancer Biology & Co-CSO) | Sale | 12,763 | 7.63 | 97,445 |
| 2017-01-03 | Hoey Timothy (SVP, Cancer Biology & Co-CSO) | Option Ex | 12,763 | 1.43 | 18,251 |
| 2016-11-16 | Hoey Timothy (SVP, Cancer Biology & Co-CSO) | Sale | 12,500 | 9.89 | 123,612 |
| 2016-11-16 | Hoey Timothy (SVP, Cancer Biology & Co-CSO) | Option Ex | 12,500 | 1.43 | 17,875 |
| 2016-01-11 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 20.01 | 50,020 |
| 2016-01-11 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2016-01-07 | Hager Alicia J. (VP & General Counsel) | Sale | 1 | 21.33 | 21 |
| 2016-01-07 | Gurney Austin (See Remarks) | Sale | 1 | 21.33 | 21 |
| 2016-01-07 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 1 | 21.33 | 21 |
| 2016-01-07 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1 | 21.33 | 21 |
| 2016-01-07 | Hoey Timothy (SVP, Cancer Biology) | Sale | 1 | 21.33 | 21 |
| 2016-01-07 | Patel Sunil (See Remarks) | Sale | 1 | 21.33 | 21 |
| 2016-01-06 | Hager Alicia J. (VP & General Counsel) | Sale | 1,622 | 21.92 | 35,557 |
| 2016-01-06 | Gurney Austin (See Remarks) | Sale | 2,161 | 21.92 | 47,369 |
| 2016-01-06 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 2,161 | 21.93 | 47,395 |
| 2016-01-06 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,161 | 21.92 | 47,369 |
| 2016-01-06 | Hoey Timothy (SVP, Cancer Biology) | Sale | 2,161 | 21.93 | 47,390 |
| 2016-01-06 | Patel Sunil (See Remarks) | Sale | 2,161 | 21.98 | 47,492 |
| 2016-01-06 | Hastings Paul J (Chairman & CEO) | Sale | 2,412 | 21.92 | 52,875 |
| 2015-12-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 20.49 | 51,232 |
| 2015-12-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2015-11-27 | Hager Alicia J. (VP & General Counsel) | Sale | 1,800 | 23.14 | 41,653 |
| 2015-11-27 | Hager Alicia J. (VP & General Counsel) | Option Ex | 1,800 | 3.42 | 6,156 |
| 2015-11-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 21.17 | 52,922 |
| 2015-11-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2015-10-27 | Hager Alicia J. (VP & General Counsel) | Sale | 5,400 | 21.00 | 113,400 |
| 2015-10-27 | Hager Alicia J. (VP & General Counsel) | Option Ex | 5,400 | 3.42 | 18,468 |
| 2015-10-26 | Gurney Austin (See Remarks) | Sale | 14,000 | 20.00 | 280,000 |
| 2015-10-26 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 5,000 | 20.00 | 100,000 |
| 2015-10-26 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 5,000 | 4.56 | 22,799 |
| 2015-09-30 | Lasersohn Jack W | Buy | 11,210 | 15.60 | 174,887 |
| 2015-09-29 | Lasersohn Jack W | Buy | 3,140 | 14.15 | 44,431 |
| 2015-09-28 | Lasersohn Jack W | Buy | 10,000 | 14.73 | 147,350 |
| 2015-08-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 22.25 | 55,622 |
| 2015-08-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2015-07-30 | Gurney Austin (See Remarks) | Sale | 7,000 | 21.24 | 148,687 |
| 2015-07-29 | Gurney Austin (See Remarks) | Sale | 7,000 | 20.68 | 144,760 |
| 2015-07-28 | Hager Alicia J. (VP & General Counsel) | Sale | 1,800 | 21.00 | 37,800 |
| 2015-07-28 | Hager Alicia J. (VP & General Counsel) | Option Ex | 1,800 | 3.42 | 6,156 |
| 2015-07-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 20.13 | 50,325 |
| 2015-07-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2015-07-06 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 2,500 | 21.22 | 53,050 |
| 2015-07-06 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 2,500 | 4.56 | 11,399 |
| 2015-06-29 | Hager Alicia J. (VP & General Counsel) | Sale | 1,800 | 22.66 | 40,797 |
| 2015-06-29 | Hager Alicia J. (VP & General Counsel) | Option Ex | 1,800 | 3.42 | 6,156 |
| 2015-06-22 | Hoey Timothy (SVP, Cancer Biology) | Sale | 5,000 | 26.07 | 130,335 |
| 2015-06-22 | Hoey Timothy (SVP, Cancer Biology) | Option Ex | 5,000 | 1.43 | 7,150 |
| 2015-06-16 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 8,500 | 25.22 | 214,336 |
| 2015-06-16 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 8,500 | 2.42 | 20,612 |
| 2015-06-15 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 8,500 | 24.92 | 211,794 |
| 2015-06-15 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 8,500 | 1.43 | 12,155 |
| 2015-05-27 | Hager Alicia J. (VP & General Counsel) | Sale | 1,800 | 23.07 | 41,527 |
| 2015-05-27 | Hager Alicia J. (VP & General Counsel) | Option Ex | 1,800 | 3.42 | 6,156 |
| 2015-05-18 | Gurney Austin (See Remarks) | Sale | 4,000 | 22.76 | 91,040 |
| 2015-04-27 | Hager Alicia J. (VP & General Counsel) | Sale | 1,800 | 25.68 | 46,218 |
| 2015-04-27 | Hager Alicia J. (VP & General Counsel) | Option Ex | 1,800 | 3.42 | 6,156 |
| 2015-04-27 | Hoey Timothy (SVP, Cancer Biology) | Sale | 6,887 | 25.66 | 176,747 |
| 2015-04-27 | Hoey Timothy (SVP, Cancer Biology) | Option Ex | 5,000 | 1.43 | 7,150 |
| 2015-04-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 26.00 | 103,980 |
| 2015-04-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 26.51 | 39,765 |
| 2015-04-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2015-04-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 8,500 | 25.49 | 216,699 |
| 2015-04-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 8,500 | 1.43 | 12,155 |
| 2015-04-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 8,500 | 25.19 | 214,106 |
| 2015-04-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 8,500 | 1.43 | 12,155 |
| 2015-03-20 | Patel Sunil (See Remarks) | Sale | 14,665 | 27.86 | 408,537 |
| 2015-03-20 | Patel Sunil (See Remarks) | Option Ex | 14,665 | 3.42 | 50,154 |
| 2015-03-19 | Patel Sunil (See Remarks) | Sale | 3,335 | 27.34 | 91,185 |
| 2015-03-19 | Patel Sunil (See Remarks) | Option Ex | 3,335 | 3.42 | 11,405 |
| 2015-03-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 27.37 | 109,468 |
| 2015-03-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 27.17 | 40,753 |
| 2015-03-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2015-02-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 26.37 | 105,492 |
| 2015-02-10 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 24.23 | 36,351 |
| 2015-02-10 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2015-02-05 | Hoey Timothy (SVP, Cancer Biology) | Sale | 7,500 | 22.83 | 171,240 |
| 2015-02-05 | Hoey Timothy (SVP, Cancer Biology) | Option Ex | 7,500 | 1.43 | 10,725 |
| 2015-02-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 22.49 | 89,952 |
| 2015-02-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2015-01-20 | Gurney Austin (See Remarks) | Sale | 4,000 | 23.27 | 93,076 |
| 2015-01-12 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 26.12 | 39,184 |
| 2015-01-12 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2015-01-05 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 7,500 | 23.00 | 172,500 |
| 2015-01-05 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 7,500 | 4.56 | 34,200 |
| 2015-01-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 22.41 | 89,632 |
| 2015-01-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-12-31 | Pollard-knight Denise | Sale | 3,799 | 21.66 | 82,301 |
| 2014-12-30 | Pollard-knight Denise | Sale | 5,510 | 21.65 | 119,285 |
| 2014-12-29 | Pollard-knight Denise | Sale | 9,902 | 21.62 | 214,051 |
| 2014-12-26 | Pollard-knight Denise | Sale | 2,195 | 21.65 | 47,517 |
| 2014-12-19 | Pollard-knight Denise | Sale | 20,654 | 21.71 | 448,315 |
| 2014-12-18 | Root Jonathan D (Director) | Sale | 13,052 | 21.05 | 274,783 |
| 2014-12-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.00 | 80,000 |
| 2014-12-10 | Pollard-knight Denise | Sale | 7,940 | 21.77 | 172,885 |
| 2014-12-09 | Pollard-knight Denise | Sale | 23,273 | 21.78 | 506,979 |
| 2014-12-08 | Pollard-knight Denise | Sale | 1,727 | 21.68 | 37,434 |
| 2014-12-05 | Pollard-knight Denise | Sale | 25,000 | 21.84 | 546,025 |
| 2014-12-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 21.19 | 84,752 |
| 2014-12-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-11-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.16 | 80,660 |
| 2014-11-05 | Hoey Timothy (SVP, Cancer Biology) | Sale | 2,500 | 19.51 | 48,765 |
| 2014-11-05 | Hoey Timothy (SVP, Cancer Biology) | Option Ex | 2,500 | 1.43 | 3,575 |
| 2014-11-03 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 20.45 | 81,820 |
| 2014-11-03 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-10-29 | Hastings Paul J (Chairman & CEO) | Sale | 8,385 | 21.90 | 183,614 |
| 2014-10-29 | Hastings Paul J (Chairman & CEO) | Option Ex | 8,385 | 1.43 | 11,990 |
| 2014-10-28 | Hastings Paul J (Chairman & CEO) | Sale | 8,384 | 22.08 | 185,127 |
| 2014-10-28 | Hastings Paul J (Chairman & CEO) | Option Ex | 8,384 | 1.43 | 11,989 |
| 2014-10-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.07 | 80,280 |
| 2014-10-02 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.00 | 80,000 |
| 2014-10-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 5,809 | 20.00 | 116,180 |
| 2014-10-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 5,809 | 1.43 | 8,306 |
| 2014-09-04 | Lasersohn Jack W | Buy | 170 | 17.50 | 2,975 |
| 2014-09-03 | Lasersohn Jack W | Buy | 3,000 | 18.40 | 55,199 |
| 2014-09-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 2,191 | 20.00 | 43,830 |
| 2014-09-02 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 2,191 | 1.43 | 3,133 |
| 2014-08-22 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.00 | 80,000 |
| 2014-08-21 | Pakianathan Deepika (Director) | Buy | 21,603 | 18.98 | 409,981 |
| 2014-08-20 | Pakianathan Deepika (Director) | Buy | 46,059 | 19.00 | 874,982 |
| 2014-08-19 | Pakianathan Deepika (Director) | Buy | 12,541 | 18.89 | 236,886 |
| 2014-08-15 | Lasersohn Jack W | Buy | 1,045 | 17.00 | 17,765 |
| 2014-08-05 | Hoey Timothy (SVP, Cancer Biology) | Sale | 2,500 | 21.95 | 54,877 |
| 2014-08-05 | Hoey Timothy (SVP, Cancer Biology) | Option Ex | 2,500 | 1.43 | 3,575 |
| 2014-08-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 20.98 | 83,912 |
| 2014-08-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-07-29 | Hastings Paul J (Chairman & CEO) | Sale | 8,385 | 22.28 | 186,801 |
| 2014-07-29 | Hastings Paul J (Chairman & CEO) | Option Ex | 8,385 | 1.43 | 11,990 |
| 2014-07-28 | Hastings Paul J (Chairman & CEO) | Sale | 8,385 | 22.31 | 187,102 |
| 2014-07-28 | Hastings Paul J (Chairman & CEO) | Option Ex | 8,385 | 1.43 | 11,990 |
| 2014-07-23 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 23.00 | 34,500 |
| 2014-07-23 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2014-07-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 20.46 | 81,852 |
| 2014-07-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 24.06 | 96,228 |
| 2014-07-01 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-06-30 | Pollard-knight Denise | Sale | 11,485 | 23.59 | 270,919 |
| 2014-06-26 | Dupont Jakob (SVP & Chief Medical Officer) | Sale | 1,500 | 23.00 | 34,503 |
| 2014-06-26 | Dupont Jakob (SVP & Chief Medical Officer) | Option Ex | 1,500 | 4.56 | 6,839 |
| 2014-06-25 | Pollard-knight Denise | Sale | 3,252 | 23.56 | 76,623 |
| 2014-06-24 | Pollard-knight Denise | Sale | 11,764 | 23.57 | 277,324 |
| 2014-06-23 | Pollard-knight Denise | Sale | 52,797 | 24.20 | 1,277,423 |
| 2014-06-17 | Gurney Austin (See Remarks) | Sale | 4,000 | 24.99 | 99,964 |
| 2014-06-16 | Lewicki John A. (EVP & Chief Scientific Officer) | Sale | 4,000 | 24.59 | 98,348 |
| 2014-06-16 | Lewicki John A. (EVP & Chief Scientific Officer) | Option Ex | 4,000 | 1.43 | 5,720 |
| 2014-06-10 | Root Jonathan D (Director) | Sale | 4,800 | 24.48 | 117,504 |
| 2014-06-10 | Usvp Entrepreneur Partners Viii B L P (10% Owner) | Sale | 4,800 | 24.48 | 117,504 |
| 2014-06-09 | Root Jonathan D (Director) | Sale | 8,252 | 24.62 | 203,164 |
| 2014-06-09 | Usvp Entrepreneur Partners Viii B L P (10% Owner) | Sale | 8,252 | 24.62 | 203,164 |
| 2014-05-15 | Federman Irwin (10% Owner) | Sale | 28,956 | 22.51 | 651,799 |
| 2014-05-12 | Young Philip M (10% Owner) | Sale | 46,327 | 21.98 | 1,018,499 |
Insider trading activities including stock purchases, stock sales, and option exercises of OMED listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Oncomed Pharmaceuticals Inc (symbol OMED, CIK number 1302573) see the Securities and Exchange Commission (SEC) website.